Product How it works Pricing Blog FAQ About Contact
Profarma

Profarma (B3: PFRM3) net income

Profarma reported a net profit of BRL 118.9m for fiscal 2025, 3.8% more than in fiscal 2024 (BRL 114.6m). Its net margin was 1.0%.

Net income, in millions of Brazilian reais-49.02016-112.72017-9.7201812.0201952.3202078.2202180.9202270.42023114.62024118.92025

Net income by fiscal year

Fiscal yearNet incomeChangeNet margin
2025BRL 118.9m+3.8%1.0%
2024BRL 114.6m+62.8%1.1%
2023BRL 70.4m−13.0%0.8%
2022BRL 80.9m+3.4%1.0%
2021BRL 78.2m+49.4%1.2%
2020BRL 52.3m+336.9%1.0%
2019BRL 12.0m—0.2%
2018−BRL 9.7m—−0.2%
2017−BRL 112.7m—−2.7%
2016−BRL 49.0m—−1.2%

The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of Brazilian reais, except per-share amounts.

Questions about the net income of Profarma

How much did Profarma earn in fiscal 2025?
Profarma reported a net profit of BRL 118.9m for fiscal 2025. In fiscal 2024 it reported a net profit of BRL 114.6m.
What is the net margin of Profarma?
In fiscal 2025 its net profit was 1.0% of its revenue.
What was the most profitable year for Profarma?
Of its last 10 fiscal years, fiscal 2025, with BRL 118.9m.
Where do the figures for Profarma come from?
From the annual financial statements (DFP) that Profarma files with the CVM, the Brazilian securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual financial statements (DFP) that Profarma files with the CVM, the Brazilian securities regulator. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Profarma: the Profarma page · annual accounts · revenue · dividends paid.

More companies from Brazil and the rest of the region: Latin American stocks.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.